anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compounds and methods are provided for inhibiting an aldehyde dehydrogenase (ALDH). Methods of treating cancer are also provided. The ALDH-inhibitor can be a compound that is based on a cyclic guanidine, or an imidazolium core. In certain embodiments, the ALDH-inhibitor compound is a substituted cyclic guanidine, or a substituted imidazolium compound. Aspects of the methods include methods of selectively inhibiting a particular ALDH family member. In some cases, the subject compounds are ALDH1 B1-selective inhibitors. In some cases, the subject compounds are ALDH1A3-selective inhibitors.
Adipose aquaglyceroporin (AQPap) modulators that stimulate the AQPap activity of adipocytes are used in cosmetic compositions as slimming agents for reducing the volume of adipocytes, are new. Independent claims are also included for: (1) cosmetic composition comprising an adipose aquaglyceroporin modulator as above and a lipolytic agent; (2) use of escin, proanthocyanidins, diosgenin and ginkgo extracts for modulating the aquaglyceroporins of adipose tissue. ACTIVITY : Anorectic. No biological data given. MECHANISM OF ACTION : Adipose aquaglyceroporin modulator; phosphodiesterase inhibitor; alpha -2 receptor inhibitors, neuropeptide Y inhibitors, LDL or VLDL receptor synthesis inhibitors, beta receptor activators, G-protein activators, glucose transport blockers, adenylcyclase activator. No biological data given.
Dysmenorrhea is a common gynecological disease and chronic pain disorder.Understanding the neural mechanisms of dysmenorrhea and the brain changes affecting pain factors is important for finding dysmenorrhea treatment methods. The emergence and progress of non-invasive neuroimaging technology can help us better understand pain at the neural level. Recent developments in identifying brain-based biomarkers of pain through advances in advanced imaging can provide some foundations for predicting and detecting pain. Twenty patients with dysmenorrhea and twenty matched female healthy controls were recruited from our hospital. All participants underwent the head magnetic resonance imaging scans to calculate grey matter volume and Diffusion Tensor Imaging parameters. Questionnaire assessment was also conducted.
Approximately 30 participants will be randomized 1:1 to receive either investigational phage therapy (3 x 10\^8 PFU phage(s)) or inert placebo (sterile normal saline solution) will be administered intravesicularly (instilled into the participant's bladder via catheter) twice a day (BID) for 7 days; the investigational phage therapies are personalized for each participant per phage susceptibility testing to the predominant E. coli pathogen in the participant's bladder. A mixture of up to three phages in a sterile solution will comprise the investigational phage therapy. The study duration for participants will be up to 65 days, which includes up to 30 days for screening, 7 days of IP treatment, and post-treatment assessments at Days 14, 21, 28 and 35 (7, 14, 21 and 28 days after the End of Treatment \[EOT\] on Day 7, respectively). Day 35 is defined as the EOS. The investigators will strive to enroll participants who are receiving inpatient care in the Spinal Cord Injury units, but enrollment of outpatients with SCI is also possible. Study enrollment will continue for up to 30 evaluable participants.

The study will consist of a Screening Period of up to 30 days. On Day -1, eligible participants will be randomized to investigational phage therapy or placebo. The Treatment Period (Days 1-7) is 7 days and participants will receive a total of 14 doses of IP. The EOT will be after IP dose 14 on Day 7. The Follow-up Period is 35 days starting the day after the EOT with study assessments on Days 14, 21, and Day 35 (EOS). Adverse event data will be collected throughout the study from Treatment Day 1 through the EOS.
Helicobacter pylori in known to be closely associated with the pathogenesis of gastroduodenal disorders such as peptide ulcer. Eradication of this bacterium is important in the treatment of these diseases as well as in the reduction of the recurrence. The one-week triple therapy with proton pump inhibitors (PPIs) is now considered to be the standard therapies in the treatment of Helicobacter pylori infection, providing more than 80% eradication rates with few adverse effects. PPIs are mainly metabolized by CYP2C19, which is known to exhibit polymorphisms in both its genotype and phenotype. Based on the PK/PD results of our study on PPI, recently, we have proposed that CYP2C19 poor metabolizers might be subject to advantageous conditions, especially after day-4, for the treatment of H. pylori infection when 20 mg rabeprazole was given twice daily. Our results also suggest a possibility to start the triple therapy on day-4 of rabeprazole treatment to ensure the optimal acid suppression effect for antibiotics to exert the bacteriocidal effect. To find the rationale and the optimal dosing regimen for the eradication of H. pylori infection using different proton pump inhibitors, volunteers of four groups would be included in this study. PPI (rabeprazole or esomeprazole) is given for 7 days. Antibiotics are given starting from day-1 or day-4 of PPI dosing. The eradication rate of H. pylori infection and the PK/PD of PPIs are also evaluated.
Dignity Therapy is a well tolerated structured interview that helps patients reflect on who they are, what is most important to them and what lessons they have learned through life. For patients not receiving chemotherapy, Dignity Therapy gave patients more hope, more meaning in their life, and helped their families. Researchers at Northwestern University would like to see if it has the same effect in patients getting chemotherapy. We will also see if the Dignity Therapy changes patient's understanding of their disease and their medical preferences.

All study procedures will take place when participants come for a scheduled doctor's visit or to receive chemotherapy. At the first visit participants will answer a questionnaire taking approximately 15-30 minutes. Participants will then have a Dignity Therapy Session approximately 1-2 weeks later. A second Dignity Therapy Session will be scheduled again in another 1-2 weeks. Each study Dignity Therapy Session will take approximately an hour. One to two weeks later a repeat questionnaire will be filled out. Finally, a third and final questionnaire will be complete 4 weeks later.
Background: Subcutaneous continuous glucose monitoring (CGM) may facilitate glucose control in the ICU. We aimed to assess the accuracy of CGM (Dexcom G6) against arterial blood glucose (ABG) in adult critically ill patients receiving intravenous insulin infusion and vasopressor therapy. We also aimed to assess feasibility and tolerability of CGM in this setting. Methods: We included ICU patients receiving mechanical ventilation, insulin, and vasopressor therapy. Numerical accuracy was assessed by the mean absolute relative difference (MARD), overall, across arterial glucose strata, over different noradrenaline equivalent infusion rates, and over time since CGM start. MARD <14% was considered acceptable. Clinical accuracy was assessed using Clarke Error Grid (CEG) analysis. Feasibility outcome included number and duration of interrupted sensor readings due to signal loss. Tolerability outcome included skin reactions related to sensor insertion or sensor adhesives. Results: We obtained 2946 paired samples from 40 patients (18 with type 2 diabetes) receiving a median (IQR) maximum noradrenaline equivalent infusion rate of 0.18 (0.08-0.33) µg/kg/min during CGM. Overall, MARD was 12.7% (95% CI 10.7-15.3), and 99.8% of CGM readings were within CEG zones A and B. MARD values ≥14% were observed when ABG was outside target range (6-10 mmol/L [108-180 mg/dL]) and with noradrenaline equivalent infusion rates above 0.10 µg/kg/min. Accuracy improved with time after CGM start, reaching MARD values <14% after 36 h. We observed four episodes of interrupted sensor readings due to signal loss, ranging from 5 to 20 min. We observed no skin reaction related to sensor insertion or sensor adhesives. Conclusions: In our ICU cohort of patients receiving vasopressor infusion, subcutaneous CGM demonstrated acceptable overall numerical and clinical accuracy. However, suboptimal accuracy may occur outside glucose ranges of 6-10 mmol/L (108-180 mg/dL), during higher dose vasopressor infusion, and during the first 36 h after CGM start.
L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose \~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
1,213,697. Hair dyeing. THERACHEMIE CHEMISCH THERAPEUTISCHE G.m.b.H. 26 April, 1968 [29 April, 1967], No. 19788/68. Heading D1B. A composition for dyeing hair comprises a pyrazolone derivative of formula I in which R is hydrogen, an alkyl residue of 1-6 carbon atoms or a phenyl residue, X is -NH2 -NHR1, -NR1R2, in which R, and R2 are alkyl residues of 1-4 carbort atoms or X is the -OH group, and an aromatic di- or polyfunctional amine with at least one primary amino group and a further functional group defined as -OH, -NH2, -NHR1 or -NR1R2 in which R1 and R2 are alkyl or hydroxyalkyl having 1-4 carbon atoms, in the para position or a 4-amino-pyrazolone. Preferably the 4- aminopyrazolone is of formula II which R3 and R4 are hydrogen or an organic residue having 1-10 carbon atoms. The dyes are applied to hair in conjunction with a developer, e.g. hydrogen peroxide at 15-40‹C. and art alkaline pH values in presence of thickening and/or wetting agents.
Single doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.
The present invention relates to a wash-off-type scalp or hair cleansing composition having a hair cleaning effect and adding color to hair, darkening hair, or preventing dyed hair from being faded. The present invention comprises: (1) a first agent of a shampoo base including a tannic acid, an anionic surfactant, and a cationic polymer; and (2) a second agent of a conditioner base including a water-soluble metal salt, a higher alcohol, and a cationic surfactant. A composition for cleaning the scalp or hair according to the present invention comprises a tannic acid and a water-soluble metal salt. Accordingly, tannic acid, which has long lasting power not to be easily washed by hair washing, is adsorbed to a hair surface. Then, a water-soluble metal salt not only strengthens the bonding between a tannic acid and hair. Also, by adding color by combination with a tannic acid, it is possible to darken the color of hair or improve the fading of dyed hair to improve color retention.
Cystic fibrosis therapy and compositions for cystic fibrosis therapy are disclosed. Methods of modulating autophagy activity and compositions for modulating autophagy activity are disclosed. In specific aspects, antagomirs that comprise a nucleic acid that hybridizes to a Mir17-92 cluster under moderate or high stringent conditions are disclosed. Pharmaceutical compositions comprising these antagomirs and a pharmaceutically acceptable carrier are also disclosed. Methods of using these pharmaceutical compositions to treat a patient with cystic fibrosis, increasing clearance of infection in a patient with cystic fibrosis, reducing inflammation in a patient, modulating autophagy activity in a patient, increasing CFTR function in a patient, and treating other related diseases are also disclosed. Methods of assaying levels of Mir17-92 expression are also disclosed.
PURPOSE:To improve the precision in specifying the electric current source position by forming a correct shape conductor model by using the data synchronized with the aspiration operation as the measured magnetic tield distribution data of an intra- living body activity electric current imaging device. CONSTITUTION:Into an electric current source position calculation part 3, the tomography image data obtained from an aspiration-synchronized pulse 23, aspiration, magnetic field data of the trunk body outside which is obtained from the heart-beat-synchronized pulse 25, and the electrocardiograph output as the initial value setting data are inputted, A shape conductor model is prepared from the tomography image data. Then, the initial value is set, and the magnetic field distribution calculation is carried out, and this data and the measured magnetic field distribution data of the trunk body outside which is obtained from the aspiration heart-beat-synchronized pulse 25 are compared, and it is judged if the difference between both is within a prescribed value range or not. If the result is 'NO', the electric current source position is shifted, and the 'magnetic field-collation' processing is repeated. If the result is 'OK', the data is sent into a display part 5, and superposed to the tomography image data which is previously inputted, and the result is displayed. Accordingly, the position of a diseased part can be known correctly.
Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m\^2.
Liver cirrhosis, a common liver disease, currently lacks specific targeted therapies. This study investigates the potential therapeutic effects of serum circulating proteins on cirrhosis from a genetic perspective, and identified six associated plasma proteins (SERPINA1, PSG5, NCAN, APOE, ADH1B, GM2A). To search for therapeutic drugs associated with circulating proteins, databases such as DrugBank and DGIdb are utilized. Phenome-wide Mendelian Randomization analysis of the six significantly associated proteins revealed that GM2A exhibited no notable side effects as a therapeutic target for cirrhosis, SERPINA1 may offer additional therapeutic benefits for cholelithiasis and emphysema. ADH1B serves as a potential drug target that could simultaneously reduce the risk of alcohol-related disorders and hypertension. Furthermore, PSG5 and APOE might increase the risk of cardiovascular and neurological diseases, and NCAN has the potential to additionally reduce the risk of developing non-alcoholic fatty liver disease NAFLD. In conclusions, this study substantiates, from a genetic perspective, the potential therapeutic target role of six plasma proteins in cirrhosis, while comprehensively evaluating their side effects.
A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas was recruited in 1987. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. The recommended dosage of ulinastatin is 300,000 IU, q8h (Continuous administration for more than 5 days).
The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
The control application will provide links to helpful resources for patients with cancer, such as the contact information for cancer support services at Northwestern University and the University of Miami, and the link to the National Cancer Institute website, and the American Cancer Society website. Control participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy. Patients also undergo blood sample collection prior to therapy (within 7 days of starting radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their medical records are reviewed for up to 2 years.
Usual daily dose, 10 to 20 mg/lb (25 to 50 mg/kg) body weight divided in four equal doses.

Therapy should be continued for at least 24 to 48 hours after symptoms and fever have subsided.

For treatment of brucellosis, 500 mg tetracycline q.i.d. for three weeks should be accompanied by streptomycin, 1 gram intramuscularly twice daily the first week and once daily the second week.

For the treatment of syphilis in patients allergic to penicillin, the following dosage of tetracycline is recommended: early syphilis (less than one year’s duration), 500 mg q.i.d. for 15 days. Syphilis of more than one year’s duration (except neurosyphilis), 500 mg q.i.d. for 30 days.

For treatment of gonorrhea, the recommended dose is 500 mg by mouth four times a day for seven days.

In cases of moderate to severe acne which, in the judgement of the clinician, require long-term treatment, the recommended initial dosage is 1 gram daily in divided doses. When improvement is noted, dosage should be gradually reduced to maintenance levels ranging from 125 mg to 500 mg daily. In some patients it may be possible to maintain adequate remission of lesions with alternate-day or intermittent therapy. Tetracycline therapy of acne should augment the other standard measures known to be of value. Duration of long-term treatment which can safely be recommended has not been established (see WARNINGS and Carcinogenesis, Mutagenesis, Impairment of Fertility).
Participants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.
ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
The invention provides chitosan-modified methazolamide solid lipid nanoparticles and a preparation method thereof. The chitosan-modified methazolamide solid lipid nanoparticles can be used as eye drops. The preparation method is suitable for industrial production. The chitosan-modified methazolamide solid lipid nanoparticles are characterized in that based on 30ml of a nanoparticle-containing solution, the chitosan-modified methazolamide solid lipid nanoparticles comprise 5mg of methazolamide, 25 to 150mg of at least one lipid material, 25 to 150mg of phospholipid, 5 to 100mg of chitosan, 50 to 250mg of at least one non-phospholipid surfactant and 50 to 250mg of at least one assistant surfactant. The chitosan-modified methazolamide solid lipid nanoparticles have small particle sizes and high drug entrapment efficiency. Compared with solid lipid nanoparticles which are not modified by chitosan, the chitosan-modified methazolamide solid lipid nanoparticles have higher stability and better corneal permeability because of positive charges on the surfaces of the chitosan-modified methazolamide solid lipid nanoparticles so that drug bioavailability is improved. Therefore, the chitosan-modified methazolamide solid lipid nanoparticles have a large clinical application potential in glaucoma treatment.
Diabetes has become one of the major chronic non-communicable diseases. Its prevalence was rising in these years. Short-term intensive insulin therapy can improve the β-cell function and nearly half of the patients can live with long-term glycemic remission. It has therefore become the recommended treatment for the newly diagnosis T2DM patients with high blood glucose. However, due to the glycemic goal for intensive therapy is strict, it's important to find out a suitable initial insulin regimen for continuous subcutaneous insulin infusion(CSII) with which patients can achieve euglycemia safely, stably and rapidly. In previous study, the investigators found out that the total daily insulin dose at the first day when euglycemia was achieved（TDD-1） was associated with weight, waist circumference, triglycerides and fasting blood glucose levels. According to this, the investigators figured out a formula for estimation of insulin dose for the short-term intensive insulin therapy in patients with newly diagnosed T2DM. However, its feasibility needs to be further verified. Therefore, the investigators conducted this prospective randomized controlled study to compare the effects of different initial insulin dose regimens during the short-term insulin intensive treatment on time to glycemic goal, hypoglycemia prevalence, glycemic variability and other safety problems in newly diagnosed type 2 diabetes patients, in order to investigate the rational of formula based initiation regimen.
Heart team has been recommended by guideline for optimizing the decision making for patients with complex coronary artery diseases (CAD). However, prior studies have demonstrated that heart team decision might have poor reproducibility, and the variability of heart team decision remains unknown.

Thus, the investigators designed a single-center, retrospective, cross-sectional study to explore the decision variability of heart team in CAD patients. The investigators will retrospectively recruit patients with angiographically confirmed 3-vessel or left main disease from a coronary angiography database at Fuwai hospital. Patients' baseline information will be collected. And different heart teams will be established and made decisions for the enrolled patients. First, the investigators will assess the decision variability between different heart teams. Secondary, the investigators will evaluate the reason of discrepancy by qualitative and quantitative analysis.
Cysts are abnormal fluid-filled sacs found in various human organs, including the liver. Liver cysts can be associated with known causes such as parasite infections and gene mutations, or simply aging. Among these causes, simple liver cysts are often found in elderly people. While they are generally benign, they may occasionally grow but rarely shrink with age, indicating their clear association with aging. However, the mechanism behind the formation of simple liver cysts has not been thoroughly investigated. Recently, we have generated transgenic mice that specifically overexpress fibroblast growth factor (FGF)18 in hepatocytes. These mice exhibit severe liver fibrosis without inflammation and spontaneously develop liver cysts that grow with age. Our findings suggest that simple liver cysts can be induced by fibrosis accompanied by sterile inflammation or injury, whereas fibrosis accompanied by severe inflammation or injury may lead to cirrhosis. We also discuss the detrimental effects of disease- and aging-associated fibrosis in various organs, such as the heart, lungs, and kidneys. Additionally, we provide a brief summary of the two currently approved anti-fibrotic drugs for idiopathic pulmonary fibrosis, nintedanib and pirfenidone, as well as their possibility of future expansion of application toward other fibrotic diseases.